GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Computational Science and Intelligent Technologies, MNAA Pub World, Vol. 3, No. 1 ( 2022), p. 17-23
    Abstract: A developing technology gaining interest from numerous researchers in current commercial and academic domains is known as “digital twinning” (DT). Growth has accelerated thanks to technological advances, particularly in the industrial industries. Data from both physical and virtual machines are combined in both directions. The Internet of Things (IoT) and Artificial Intelligence (AI) are two examples of the many difficulties, applications, and technical integrations that come with digital twinning. This work thoroughly reviews and explores the notion of digital twinning. The study topics that were the focus of this survey were health care, business, smart cities, and weatherbased applications. It reflects how people currently view the research field. Examining enabling twinning technologies, open problems, and applications of digital twinning are made easier by this study.
    Type of Medium: Online Resource
    ISSN: 2582-9041
    URL: Issue
    Language: Unknown
    Publisher: MNAA Pub World
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Binaytara Foundation ; 2023
    In:  International Journal of Cancer Care and Delivery
    In: International Journal of Cancer Care and Delivery, Binaytara Foundation
    Abstract: The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several ICI approved for the management of NSCLC based on the PD-L1 expression of the tumors. PD-L1 is a controversial biomarker with various inconsistencies in expression owing to temporal and spatial heterogeneity. Tumor mutational burden is another much studied biomarker associated with its own challenges and questionable concordance with tumor PD-L1 expression. In this article, we aim to discuss the challenges associated with the existing biomarkers, highlighting the need for emerging biomarkers that can help with decision making in the management of this there where several therapeutic options exist. There are emerging “me too” PD-1/PD-L1 drugs which may serve its purpose in many counties where there is limited access to current approved ICIs. What is increasingly apparent is the need to move the needle forward in the treatment of NSCLC and we will discuss the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.
    Type of Medium: Online Resource
    ISSN: 2770-3533
    Language: English
    Publisher: Binaytara Foundation
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Frontiers Media SA ; 2023
    In:  Frontiers in Oncology Vol. 13 ( 2023-9-12)
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 13 ( 2023-9-12)
    Abstract: We investigated the biological predisposition to site of metastasis in patients with NSCLC based on their molecular profiling and program death ligand PD-L1 status. We sought to identify any association between metastatic site and molecular profile in NSCLC patients. Methods This was a retrospective analysis of patients with stage IV NSCLC who were newly diagnosed from January 2014 to June 2022. Clinical characteristics, pathology, molecular reports, and imaging were retrieved and analyzed. Results A total of 143 patients were included in the study. Median age was 65 years, with an equal number of men (n=71) and women (n=72). The most common histology was adenocarcinoma (81.8%). At least one genetic mutation was discovered in 100 patients. Mutations with a targetable drug were found in 86 patients. The most common mutations were TP53 (25.2%), EGFR (24.5%), KRAS/NRAS (20.3%), and CDKN2A/2B (7.7%). Patients with any mutation were significantly more likely to have metastatic disease to the brain (57% vs . 37%, p=0.03), but there was no difference in metastatic disease to bone (34% vs . 26%, p=0.32). Patients without a discoverable mutation were significantly more likely to have metastatic disease to other sites (e.g., adrenal gland 91% vs . liver 66%, p=0.002). There was no difference in progression-free survival (PFS) or overall survival (OS) between those with versus without mutations. Median PFS and OS were significantly longer in patients with an EGFR mutation than those with KRAS/NRAS or TP53 mutations. Patients with PD-L1 & gt;1% or TP53 were significantly more likely to have metastatic disease to organs other than bone or brain (p=0.047 and p=0.023, respectively). We identified four prognostic groups in metastatic NSCLC. Patients with PD-L1 & lt;1% and no actionable mutations have the poorest prognosis, with median survival of around 20 months. Conclusion Patients with mutations discoverable on NGS are more likely to have metastatic disease to the brain. KRAS/NRAS in particular has a predilection to metastasize to the brain and bone. PD-L1 expression and a TP53 mutation, on the other hand, tend to lead to metastasis of NSCLC to organs other than brain or bone. These results need to be corroborated in larger prospective studies.
    Type of Medium: Online Resource
    ISSN: 2234-943X
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2023
    detail.hit.zdb_id: 2649216-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Informa UK Limited ; 2023
    In:  Cancer Investigation Vol. 41, No. 1 ( 2023-01-02), p. 12-24
    In: Cancer Investigation, Informa UK Limited, Vol. 41, No. 1 ( 2023-01-02), p. 12-24
    Type of Medium: Online Resource
    ISSN: 0735-7907 , 1532-4192
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2023
    detail.hit.zdb_id: 2043112-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: The American Journal of Human Genetics, Elsevier BV, Vol. 109, No. 2 ( 2022-02), p. 282-298
    Type of Medium: Online Resource
    ISSN: 0002-9297
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2022
    detail.hit.zdb_id: 1473813-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Journal of the American College of Cardiology, Elsevier BV, Vol. 71, No. 11 ( 2018-03), p. A663-
    Type of Medium: Online Resource
    ISSN: 0735-1097
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 1468327-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  Journal of Clinical Oncology Vol. 40, No. 16_suppl ( 2022-06-01), p. 12128-12128
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. 12128-12128
    Abstract: 12128 Background: Major stressful life events have been shown to be associated with an increased risk of lung cancer, breast cancer and the development of various chronic illnesses. The stress response generated by our body results in a variety of physiological and metabolic changes which can affect the immune system, endocrine system and metabolism which has been shown to be associated with tumor progression. There is an indication that stress may need to be considered as a risk factor for malignancies. Methods: This is a matched case control study. The objective of this study was to determine if major stressful life events are associated with the incidence of head, neck, and pancreatic cancer (HNPC). Cases (CA) were HNPC patients diagnosed within the previous 12 months. Controls (CO) were patients without a prior history of malignancy and were matched with the cases by age and smoking status. Basic demographic data and medical information were collected from the patient’s medical records. Data on major stressful life events were collected using the modified Holmes-Rahe stress scale, and the following variables: death of a spouse, death of a child/immediate family member, serious personal illness, divorce/separation, loss of a job, caring for ill family member, financial difficulties, relocation, stress at work, detention/incarceration and retirement. A total sample of 300 was needed (100 cases, 200 controls) to achieve at least 80% power to detect odds ratios (OR) of 2.00 or higher at 5% level of significance. Results: From January 2018 to August 2021, 278 patients were enrolled (CA = 77, CO = 201) matched for mean age (years) (CA = 63, CO = 64), median smoking exposure (years) (CA = 36, CO = 38). About 65% of patients in CA group and 49% of CO group were male and 54% and 46% of the CA and CO groups respectively were of white race. In a multivariable logistic regression analysis after controlling for potential confounding variables (including sex, age, race, education, marital status, smoking history), there was no difference in lifetime incidence of major stressful event between the cases and controls. However, patients with HNPC were significantly more likely to report a major stressful life event within past 5 years when compared to CO [OR = 2.59 (1.24, 5.44), p = 0.012]. Conclusions: Patients with head, neck and pancreatic cancers are significantly associated with having a major stressful life event within 5 years of their diagnosis. This study highlights the potential need to recognize stressful life events as risk factors for developing malignancies and consider incorporating early rehabilitative efforts for major life stressful events.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 16_suppl ( 2023-06-01), p. e23001-e23001
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e23001-e23001
    Abstract: e23001 Background: Evidence-based education is crucial for meeting the evolving needs of learners in the oncology workforce. In this new virtual era, engagement of trainees in educational presentations has become increasingly difficult and reaping the benefits of a conventional didactic learning environment is challenging. Case-based learning is a relatively newer modality that is being used more commonly in teaching programs. In this study, we aimed to incorporate a novel, interactive case-based learning paradigm to improve fundamental knowledge and engagement among oncology trainees. Methods: We conducted six case conferences over 6 months. The case conferences were designed to encourage open discussion of real-life oncology cases. A faculty expert and specific topics were assigned to the presenters: colon, breast, gastric, hepatocellular (HCC), prostate, and non-small cell lung (NSCLC) cancer. Guidelines on the preparation of the case presentation were provided with 5 main pillars: specific staging/workup, first-line management with a landmark trial, second-line management, case-specific challenges, and mechanism of action and monitoring parameters for discussed drugs. Fellows completed a pre- and post-conference survey that assessed their perceived comfort level with the topic, quality of the presentation (post-conference) utilizing the 1–5 Likert scale (5 being extremely satisfied/comfortable), and test questions. Results: Nearly all of the 6 fellows responded to all surveys. The table shows the mean scores given by fellows on the surveys using the Likert scale and the percentage of test questions answered correctly. Overall, the fellows felt that the case conferences were a worthwhile experience. When comparing pre- and post-conference questions, the percentage of test questions correct overall improved for 5 of 6 conferences. Conclusions: The results of our study could have implications for the curriculum planning of hematology/oncology fellowships. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  Journal of Clinical Oncology Vol. 40, No. 28_suppl ( 2022-10-01), p. 251-251
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 28_suppl ( 2022-10-01), p. 251-251
    Abstract: 251 Background: Oncologists are faced with sharing complex information to their patients when making new cancer diagnoses. Patients often find themselves overwhelmed with the amount of information given to them at this initial visit. This challenging and emotionally charged context often result in patient dissatisfaction. Currently, most patient education is done verbally despite studies showing that patients only retain 14% of verbal communication, compared to 85% when using visual aids (VA).. Gunn et al. showed that cancer patients may be vulnerable to poorer outcomes during treatment if they lack the necessary skills such as health literacy to meet the high informational demands and manage psychosocial stressors. Garcia-Retamero et al showed that the use of VA enables patients across all literacy levels to arrive at better diagnostic inferences; however, the quality and quantity of VA used is not uniform nationwide and little data exists on their use in cancer diagnosis education. Our initiative aims to improve the patient education process at our cancer center. Methods: We developed VA for breast, colon, gastric, and lung cancer clinics. New patients were divided into two, a control arm (CA) which received the current standard education and an intervention arm (IA), which also received VA. Patient surveys based on physician consensus were used to collect patient outcomes. The primary outcomes included patients’ understanding of their diagnosis, the stage of their cancer, and the goal of treatment (cure versus life prolongation). Secondary outcomes included duration of clinic visit and retention of information assessed in a follow up phone call. Results: Sixteen (16) patients participated in the study with 8 in the CA and 8 in the IA group, including 11 females and 5 males. There were 8 Caucasian, 4 African American, 2 Asian and 2 Hispanic patients. Five patients (63%) had breast cancer and 3 (38%) had lung cancer in each arm. CA had 5 patients (63%) with Stage IV disease and IA had 4 patients (50%) with Stage IV disease. IA had better understanding of the goal of treatment (100% IA vs 75% CA, p = 0.13); on follow up, IA were able to better recall the stage of their cancer (88% IA vs 63% CA, p = 0.17) and treatment goal (88% IA vs 50% CA, p = 0.08). IA arm expressed better ability to understand what was communicated to them during the visit (mean score: CA = 4.83, IA = 3.67, p = 0.01). All patients who received the pictorial educational material felt that it helped them better understand the medical information. The total visit time in minutes was 58.67 in in the CA and 44.50 in the IA (p = 0.16). Conclusions: Despite being a small study, we demonstrated a trend towards improved understanding of cancer stage and treatment goal in patients with the use of VA vs standard verbal education. In patients with newly diagnosed breast and lung cancer, the intervention also resulted in lower total visit time. This proof of concept should be reproduced in a larger study.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 6_suppl ( 2023-02-20), p. 326-326
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 6_suppl ( 2023-02-20), p. 326-326
    Abstract: 326 Background: Renal transplant recipients (RTRs) are at an increased risk of developing solid organ malignancies. Given improved allograft survival and life expectancy, the incidence of prostate cancer (PC) in RTRs appears to be increasing. Previous studies have reported the incidence of PC among RTRs to be between 0.3% and 3.24%. Limited data is available on the clinical characteristics, treatment, predictive markers, and outcomes of PC in RTRs. Methods: We performed a single-center retrospective study of male RTRs who developed PC. We collected the following data on RTRs who underwent transplantation between January 1, 1999, and December 31, 2019: baseline demographics, cause of end-stage renal disease (ESRD), duration of dialysis prior to RT, type of RT (cadaveric vs. living donor), immunosuppressive regimen, interval from RT to diagnosis of PC, stage of PC, type of treatment received, allograft survival, and overall survival (OS) were collected. Results: Among 1093 male RTRs, 15 (1.37%) developed PC. The median age at diagnosis of PC was 60 (range, 49-75) years. Subject races were African American (n=7), Hispanic (n=3), White (n=3), and other (n=2). The median duration from transplant to diagnosis of PC was 72 (range, 12-156) months. PC was diagnosed at stage I in 13 patients, stage II in 1 patient, and stage IV in 1 patient. The management of these patients consisted of local radiation (LR) alone in 6 patients, LR with leuprolide therapy in 6 patients, and radical prostatectomy alone in 1 patient. The patient with stage IV PC was treated with leuprolide and abiraterone acetate and remains progression free at follow-up of 41 months. The 5-year OS for this cohort of patients was 73.3%. Allograft function was preserved in 13 patients 12 months after diagnosis of PC. No PC-related mortality was noted. Conclusions: The incidence of PC in our analysis appears to be consistent with prior published studies. Most of our RTRs with PC had early-stage disease with excellent 5-year survival. The current standard-of-care treatment modalities for PC appear to be effective in the management of these patients. Allograft function was preserved in the majority of RTRs with PC in this study. Further research is required to evaluate the predictive factors for developing PC in RTR.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...